bladder cancer

News

FDA starts speedy review of Imfinzi in bladder cancer

AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

Ahead of ASCO data drop, AZ gets key Imfinzi approval

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

ImmunityBio rises as route opens to broader Anktiva label

Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.

FDA starts speedy review of Imfinzi in bladder cancer

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

Ahead of ASCO data drop, AZ gets key Imfinzi approval

AZ cues up broader use of Imfinzi in bladder cancer

J&J says Inlexzo follow-up 'promising' in bladder cancer

ImmunityBio rises as route opens to broader Anktiva label

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

bladder cancer

Editor's Picks